AI Engines For more Details: Perplexity Kagi Labs You
Lowering Blood Pressure: Candesartan belongs to a class of medications called angiotensin II receptor blockers (ARBs). It works by blocking the action of angiotensin II, a substance in the body that causes blood vessels to constrict, thus leading to relaxation of blood vessels and lowering of blood pressure.
Hypertension Management: Candesartan is prescribed to treat hypertension either alone or in combination with other antihypertensive medications. By reducing blood pressure, it helps to decrease the risk of heart attacks, strokes, and other cardiovascular complications associated with high blood pressure.
Heart Failure Treatment: In patients with heart failure, candesartan helps to improve symptoms, increase exercise tolerance, and reduce the risk of hospitalization related to heart failure exacerbations. It does this by reducing the strain on the heart and improving its pumping ability.
Kidney Protection: Candesartan may be used in patients with chronic kidney disease, particularly in those with proteinuria (excess protein in the urine), to slow the progression of kidney damage and reduce the risk of end-stage renal disease.
Diabetic Nephropathy: In individuals with type 2 diabetes and kidney disease (diabetic nephropathy), candesartan may be used to delay the progression of kidney damage and reduce the risk of kidney failure.
Protection of Blood Vessels: Candesartan has been shown to have protective effects on blood vessels, which can help prevent complications associated with conditions such as atherosclerosis (hardening and narrowing of the arteries), stroke, and peripheral artery disease.
Prevention of Stroke: Some studies suggest that ARBs like candesartan may help reduce the risk of stroke in certain patient populations, although further research is needed to confirm this effect.
Management of Left Ventricular Dysfunction: Candesartan may be used in patients with left ventricular systolic dysfunction following a heart attack to improve outcomes and reduce the risk of cardiovascular events.
Migraine Prevention: There is some evidence to suggest that candesartan may be effective in preventing migraines in certain individuals, although it is not a primary indication for the medication.
Potential Renoprotective Effects: Candesartan has been investigated for its potential renoprotective effects in various kidney diseases beyond diabetic nephropathy, but its use in these conditions may vary based on individual patient factors.
Rank | Probiotic | Impact |
---|---|---|
species | Escherichia coli | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.1 | 0.1 | |
ADHD | 0.2 | 0.2 | |
Age-Related Macular Degeneration and Glaucoma | 0 | 0 | 0 |
Allergic Rhinitis (Hay Fever) | 0.1 | 0.1 | |
Allergies | 0.1 | 0.1 | 0 |
Allergy to milk products | 0.1 | 0.1 | 0 |
Alzheimer's disease | 0.5 | 0.3 | 0.67 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0 | 0.1 | 0 |
Ankylosing spondylitis | 0.3 | 0.1 | 2 |
Anorexia Nervosa | 0 | 0 | 0 |
Antiphospholipid syndrome (APS) | 0.2 | 0.1 | 1 |
Asthma | 0 | 0 | 0 |
Atherosclerosis | 0.1 | 0.1 | 0 |
Atrial fibrillation | 0.1 | 0.3 | -2 |
Autism | 0.4 | 0.4 | 0 |
Barrett esophagus cancer | 0.1 | 0.1 | 0 |
benign prostatic hyperplasia | 0 | 0 | |
Bipolar Disorder | 0.2 | 0 | 0 |
Brain Trauma | 0 | 0 | |
Carcinoma | 0.3 | 0 | 0 |
Celiac Disease | 0.1 | 0.2 | -1 |
Cerebral Palsy | 0.1 | 0 | 0 |
Chronic Fatigue Syndrome | 0.2 | 0.1 | 1 |
Chronic Kidney Disease | 0.1 | 0 | 0 |
Chronic Lyme | 0 | 0 | |
Chronic Obstructive Pulmonary Disease (COPD) | 0.3 | 0 | 0 |
Chronic Urticaria (Hives) | 0.2 | 0.1 | 1 |
Coagulation / Micro clot triggering bacteria | 0.2 | 0.1 | 1 |
Colorectal Cancer | 0.7 | 0.7 | |
Constipation | 0 | 0 | 0 |
COVID-19 | 0.4 | 0.3 | 0.33 |
Crohn's Disease | 0.7 | 0.2 | 2.5 |
cystic fibrosis | 0.1 | 0 | 0 |
deep vein thrombosis | 0.1 | 0.1 | 0 |
Depression | 0.6 | 0.3 | 1 |
Dermatomyositis | 0.1 | 0.1 | |
Eczema | 0 | 0.2 | 0 |
Endometriosis | 0.2 | 0.2 | |
Eosinophilic Esophagitis | 0.1 | 0.1 | |
Epilepsy | 0.2 | 0.1 | 1 |
Fibromyalgia | 0.2 | 0.1 | 1 |
Functional constipation / chronic idiopathic constipation | 0.2 | 0.1 | 1 |
gallstone disease (gsd) | 0.1 | 0.1 | 0 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.1 | 0.1 | 0 |
Generalized anxiety disorder | 0.3 | 0 | 0 |
giant cell arteritis | 0 | 0 | |
Glioblastoma | 0.1 | -0.1 | |
Graves' disease | 0 | 0 | 0 |
Halitosis | 0.1 | 0.1 | 0 |
Hashimoto's thyroiditis | 0 | 0.1 | 0 |
Hidradenitis Suppurativa | 0.3 | 0.3 | |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.1 | 0.1 | |
hypercholesterolemia (High Cholesterol) | 0 | 0 | |
hyperglycemia | 0 | 0 | 0 |
hypersomnia | 0.1 | -0.1 | |
hypertension (High Blood Pressure | 0.1 | 0.2 | -1 |
Hypoxia | 0 | 0 | |
IgA nephropathy (IgAN) | 0.1 | -0.1 | |
Inflammatory Bowel Disease | 0.3 | 0.2 | 0.5 |
Insomnia | 0.1 | 0 | 0 |
Intelligence | 0 | 0.1 | 0 |
Intracranial aneurysms | 0 | 0 | |
Irritable Bowel Syndrome | 0.2 | 0.1 | 1 |
Liver Cirrhosis | 0.4 | 0.2 | 1 |
Long COVID | 0.3 | 0.3 | 0 |
Low bone mineral density | 0 | 0 | |
Lung Cancer | 0 | 0 | |
ME/CFS with IBS | 0.1 | 0.1 | |
ME/CFS without IBS | 0.2 | 0.2 | |
Metabolic Syndrome | 0.5 | 0.4 | 0.25 |
Mood Disorders | 0.8 | 0.3 | 1.67 |
multiple chemical sensitivity [MCS] | 0.2 | 0.2 | |
Multiple Sclerosis | 0.5 | 0.3 | 0.67 |
Neuropathy (all types) | 0.1 | 0 | 0 |
neuropsychiatric disorders (PANDAS, PANS) | 0.1 | 0.1 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.2 | 0.2 | |
Obesity | 0.3 | 0.3 | 0 |
obsessive-compulsive disorder | 0.2 | 0.1 | 1 |
Osteoarthritis | 0.1 | 0.1 | |
Osteoporosis | 0.1 | 0.1 | |
pancreatic cancer | 0.1 | 0.1 | |
Parkinson's Disease | 0.3 | 0.3 | 0 |
Polycystic ovary syndrome | 0.1 | 0 | 0 |
Postural orthostatic tachycardia syndrome | 0 | 0 | |
Premenstrual dysphoric disorder | 0 | 0 | |
Psoriasis | 0.2 | 0.2 | 0 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.6 | 0.1 | 5 |
Rosacea | 0 | 0 | |
Schizophrenia | 0.2 | 0 | 0 |
scoliosis | 0.1 | -0.1 | |
Sjögren syndrome | 0.2 | 0 | 0 |
Sleep Apnea | 0.1 | 0 | 0 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.3 | 0.3 | |
Stress / posttraumatic stress disorder | 0.3 | 0 | 0 |
Systemic Lupus Erythematosus | 0.4 | 0 | 0 |
Tic Disorder | 0.1 | -0.1 | |
Type 1 Diabetes | 0.2 | 0.1 | 1 |
Type 2 Diabetes | 0.5 | 0.3 | 0.67 |
Ulcerative colitis | 0.2 | 0.3 | -0.5 |
Unhealthy Ageing | 0.6 | 0 | 0 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.